Saltar al contenido
Merck

900661

Sigma-Aldrich

Methoxy poly(ethylene glycol)-b-poly(D,L-lactide)

4k-2.2k

Sinónimos:

mPEG-b-PLA, mPEG-PLA

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula lineal:
HO[CH(CH3)COO]m[CH2CH2O]nCH3
UNSPSC Code:
12162002
NACRES:
NA.23

Quality Level

form

powder

mol wt

PDLLA average Mn ~2,200
PEG average Mn ~4,000

storage temp.

2-8°C

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Biocompatible, amphiphilic block copolymer composed of a hydrophilic PEG block and a hydrophobic poly(D,L-lactide) (PLA) block. These materials have been used in control release and nanoparticle formulation for drug encapsulation and delivery applications. Well-defined materials with varying properties can be prepared by controlling the relative length of each polymer block. Hydroxyl termination allows for facile further chemical modification of these materials.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Ho-Chul Shin et al.
Journal of controlled release : official journal of the Controlled Release Society, 140(3), 294-300 (2009-05-05)
Current clinical and preclinical anticancer formulations are limited by their use of toxic excipients and stability issues upon combining different drug formulations. We have found that poly(ethylene glycol)-block-poly(d,l lactic acid) (PEG-b-PLA) micelles can deliver multiple poorly water-soluble drugs at clinically
Zahra Daman et al.
Pharmaceutical research, 32(11), 3756-3767 (2015-08-01)
Resistance to gemcitabine in pancreatic cancer (PC) may account for the failure of conventional treatments. Recently, salinomycin (SAL) has been identified as selective inhibitor of cancer stem cells (CSCs). In our study, we aimed to deliver SAL to gemcitabine-resistant PC
Yiguang Wang et al.
Pharmaceutical research, 27(9), 1861-1868 (2010-06-19)
To develop an efficient tumor vasculature-targeted polymeric micelle delivery system for combretastatin A4 (CA4), a novel antivascular agent. CA4-loaded micelles were prepared from poly (ethylene glycol)-b-poly (d, l-lactide) copolymers. RGD peptides that target integrins alphavbeta3 and alphavbeta5, markers of angiogenic
Yuan Zhang et al.
Pharmaceutical research, 28(5), 1167-1178 (2011-02-23)
Somatostatin analogue octreotide (OCT)-modified PEG-b-PLA micelles were constructed to bind to somatostatin receptors (SSTRs) overexpressed on tumor cells for enhanced intracellular drug delivery and improved therapeutic efficacy for malignant tumors. Copolymers conjugated with octreotide (OCT-PEG₆₀₀₀-b-PLA₅₀₀₀) were synthesized. The fluorescent probe
Rui Su et al.
Cancer cell, 38(1), 79-96 (2020-06-13)
Fat mass and obesity-associated protein (FTO), an RNA N6-methyladenosine (m6A) demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the development of effective targeted therapeutics. Here, we report two potent small-molecule FTO inhibitors that exhibit strong anti-tumor effects

Artículos

The development of drugs that target specific locations within the human body remains one of the greatest challenges in biomedicine today.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico